As of May 29, 2025, Biosig Technologies Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $5.85, this represents a potential upside of -41945479.7%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -431948.1% |
| Potential Upside (10-year) | -41945479.7% |
| Discount Rate (WACC) | 5.2% - 6.3% |
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 0 | 122% |
| 12-2025 | 0 | 481% |
| 12-2026 | 2 | 962% |
| 12-2027 | 10 | 296% |
| 12-2028 | 33 | 235% |
| 12-2029 | 103 | 214% |
| 12-2030 | 300 | 192% |
| 12-2031 | 818 | 173% |
| 12-2032 | 2093 | 156% |
| 12-2033 | 5049 | 141% |
| 12-2034 | 11422 | 126% |
Net profit margin is expected to improve from -25000% in 12-2024 to -18250% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (10) | -25000% |
| 12-2025 | (42) | -4239% |
| 12-2026 | (450) | -18250% |
| 12-2027 | (1,781) | -18250% |
| 12-2028 | (5,970) | -18250% |
| 12-2029 | (18,720) | -18250% |
| 12-2030 | (54,709) | -18250% |
| 12-2031 | (149,322) | -18250% |
| 12-2032 | (381,936) | -18250% |
| 12-2033 | (921,521) | -18250% |
| 12-2034 | (2,084,596) | -18250% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 405% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 0 |
| 12-2026 | 2 |
| 12-2027 | 10 |
| 12-2028 | 37 |
| 12-2029 | 120 |
| 12-2030 | 362 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 166 |
| Days Inventory | 717 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 9M/2025 | (43) | (12) | 1 | 0 | (32) |
| 2026 | (615) | (167) | 10 | 1 | (459) |
| 2027 | (2,430) | (659) | 40 | 2 | (1,813) |
| 2028 | (8,142) | (2,208) | 132 | 12 | (6,078) |
| 2029 | (25,524) | (6,924) | 415 | 33 | (19,048) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -431948.1% |
| 10-Year DCF (Growth) | 0.00 | -41945479.7% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Biosig Technologies Inc (BSGM) a buy or a sell? Biosig Technologies Inc is definitely a sell. Based on our DCF analysis, Biosig Technologies Inc (BSGM) appears to be overvalued with upside potential of -41945479.7%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $5.85.